Tozaki et al. identified elevated serum levels of interleukin-6 (IL-6) in patients with VEXAS syndrome, suggesting that IL-6 inhibitors like tocilizumab may offer therapeutic benefits [25]. This evidence concerns the gene IL6 and VEXAS syndrome.